Condensed Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)	Total	Promissory Notes [Member]	Preferred Stock [Member] Series A Preferred Stock [Member]	Preferred Stock [Member] Legacy Series A Preferred Stock [Member]	Preferred Stock [Member] Legacy Series C-1 Preferred Stock [Member]	Preferred Stock [Member] Legacy Series C-2 Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Additional Paid-in Capital [Member] Promissory Notes [Member]	Accumulated Deficit [Member]	Accumulated Deficit [Member] Legacy Series A Preferred Stock [Member]	Accumulated Deficit [Member] Legacy Series C-1 Preferred Stock [Member]	Accumulated Deficit [Member] Legacy Series C-2 Preferred Stock [Member]
Beginning Balance at Dec. 31, 2022	$ (37,790,539)						$ 897	$ 4,590,855		$ (42,382,291)
Beginning Balance (in Shares) at Dec. 31, 2022							896,580
Temporary equity accretion of dividends during the period				$ (151,855)	$ (37,639)	$ (437,151)					$ (151,855)	$ (37,639)	$ (437,151)
Exercise of common stock options	25,878						$ 1	25,877
Exercise of common stock options (in Shares)							14,478
Warrants issued in connection with promissory notes/preferred stock		$ 55,062							$ 55,062
Stock-based compensation expense	367,539							367,539
Net Income (Loss)	(7,137,667)									(7,137,667)
Ending Balance at Jun. 30, 2023	(45,106,372)						$ 898	5,039,333		(50,146,603)
Ending Balance (in Shares) at Jun. 30, 2023							911,058
Beginning Balance at Mar. 31, 2023	(39,743,801)						$ 897	4,777,476		(44,522,174)
Beginning Balance (in Shares) at Mar. 31, 2023							896,580
Temporary equity accretion of dividends during the period				$ (76,771)	$ (18,923)	$ (219,783)					$ (76,771)	$ (18,923)	$ (219,783)
Exercise of common stock warrants	25,878						$ 1	25,877
Exercise of common stock warrants (in Shares)							14,478
Warrants issued in connection with promissory notes/preferred stock		$ 48,950							$ 48,950
Stock-based compensation expense	187,030							187,030
Net Income (Loss)	(5,308,952)									(5,308,952)
Ending Balance at Jun. 30, 2023	(45,106,372)						$ 898	5,039,333		(50,146,603)
Ending Balance (in Shares) at Jun. 30, 2023							911,058
Beginning Balance at Dec. 31, 2023	24,749,010		$ 1				$ 2,309	83,250,101		(58,503,401)
Beginning Balance (in Shares) at Dec. 31, 2023			4,243				23,090,585
Stock received from AxoBio Disposition	(23,456,179)		$ (1)				$ (385)	(23,455,793)
Stock received from AxoBio Disposition (in Shares)			(4,243)				(3,845,337)
Common Stock issued in connection with Promissory Notes	848,500						$ 33	848,467
Common Stock issued in connection with Promissory Notes (in Shares)							328,707
Common Stock issued	2,687,225						$ 134	2,687,091
Common Stock issued (in Shares)							1,331,452
Stock-based compensation expense	375,169							375,169
Net Income (Loss)	(6,575,497)									(6,575,497)
Ending Balance at Jun. 30, 2024	(1,371,772)						$ 2,091	63,705,035		(65,078,898)
Ending Balance (in Shares) at Jun. 30, 2024							20,905,407
Beginning Balance at Mar. 31, 2024	(1,391,659)						$ 1,936	60,380,765		(61,774,360)
Beginning Balance (in Shares) at Mar. 31, 2024							19,361,068
Common Stock issued in connection with Promissory Notes	473,500						$ 21	473,479
Common Stock issued in connection with Promissory Notes (in Shares)							212,887
Common Stock issued	2,687,225						$ 134	2,687,091
Common Stock issued (in Shares)							1,331,452
Stock-based compensation expense	163,700							163,700
Net Income (Loss)	(3,304,538)									(3,304,538)
Ending Balance at Jun. 30, 2024	$ (1,371,772)						$ 2,091	$ 63,705,035		$ (65,078,898)
Ending Balance (in Shares) at Jun. 30, 2024							20,905,407